The 2025 CPhI Korea (hereinafter referred to as the Korea Pharmaceutical Exhibition) will be held at the COEX Seoul Convention Center in South Korea from August 26 to 28. The exhibition is held once a year and is organized by Informa Markets. It is one of the top ten pharmaceutical exhibitions in the world.
The 2024 Korea Pharmaceutical Exhibition CPhI Korea has entered its eighth year. This exhibition is unprecedented in scale, with a net exhibition area of 10,000 square meters. It brings together more than 360 pharmaceutical companies from all over the world. Among them, the Chinese exhibition group is particularly eye-catching, with a strong lineup of 233 companies participating in the exhibition. The exhibits cover bulk pharmaceutical raw materials, preparations, biopharmaceuticals and pharmaceutical equipment and other fields.
As an emerging growth pole, the Korean market has seen a surge in demand for exhibitions, and booth resources were once in short supply. Next year, the organizer will expand the booth area and add new exhibition halls to meet the continued high demand for exhibitions from Chinese exhibitors. During the exhibition, a number of high-standard professional forums and speeches were held simultaneously, such as “Holixer – A new era adaptogen for stress and sleep management”, “Skin quality solutions based on endogenous substances in the human body”, “Advances in liposome technology: from target to market” and “Using lipid-based preparations to improve bioavailability”. These topics are not only cutting-edge and in-depth, but also present a feast of knowledge for participants. As a global pharmaceutical manufacturing and R&D center, South Korea’s biopharmaceutical industry is booming at an unprecedented rate. According to statistics, the scale of South Korea’s pharmaceutical market in 2022 will historically exceed 25 trillion won (equivalent to about 128.58 billion yuan), setting a new high since statistics were first collected in 1998. Looking ahead, as many original drugs enter the pharmaceutical patent cliff, the Korean generic drug market will usher in a broader space for development. It is estimated that by 2027, the total volume of the global pharmaceutical market will reach an astonishing 1.9 trillion US dollars (equivalent to about 13.8 trillion yuan), showing unlimited potential. Against this background, China and South Korea have become increasingly close in the field of pharmaceutical trade and have become important economic and trade partners of each other. China is not only South Korea’s fifth largest pharmaceutical export market, but also its third largest source of pharmaceutical imports. According to the latest data, in the first seven months of 2024, the total trade volume of pharmaceuticals and health products between China and South Korea reached 3.194 billion US dollars, an increase of about 200 million US dollars over the same period last year, of which China’s exports to South Korea reached 2.39 billion US dollars, a significant year-on-year increase. The overall cumulative growth rates of imports and exports reached 6.91% and 7.42% respectively, demonstrating the steady growth trend of the two countries’ pharmaceutical cooperation.